Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29318343 | 1.00 | GBA1 (0.42) | GBA1TRPA1TRPM8MAN1B1KCNH2 | |
| SCHEMBL7227000 | 1.00 | GBA1 (0.42) | GBA1TRPA1TRPM8MAN1B1KCNH2 | |
| SCHEMBL24411181 | 0.83 | GBA1 (0.39) | GBA1FUCA1 | |
| SCHEMBL24793469 | 0.82 | TRPA1 (0.43) | GBA1TRPA1TRPM8MAN1B1FUCA1 | |
| SCHEMBL9900271 | 0.82 | TRPA1 (0.43) | GBA1TRPA1TRPM8MAN1B1FUCA1 | |
| SCHEMBL7404065 | 0.78 | — | — | |
| SCHEMBL17037474 | 0.78 | — | — | |
| SCHEMBL22768152 | 0.78 | — | — | |
| SCHEMBL10129888 | 0.78 | KCNH2 (0.33) | GBA1KCNH2 | |
| Methane SCHEMBL29263115 | 0.77 | SLC6A1 (0.35) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | GBA1 20/4885TRPA1 2991/4885TRPM8 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.